We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
While devicemakers looking to expand their direct-to-consumer (DTC) advertising efforts can benefit from drugmakers' experiences, the promotional needs of each are worlds apart, experts say.
The world’s largest retailer plans to slash the prices of close to 300 generic drugs to $4 for a month’s supply, in what is likely the biggest promotion ever to buy cheaper generic alternatives to brand drugs.
The overall cholesterol drug market is growing faster than anticipated, with the introduction of generic Zocor not hurting the competition, according to one analyst.
Baxter should change the labels on two heparin products to clearly differentiate the version used to treat adults from the one used to treat premature infants, but a broader solution would be to implement a label universal to all products routinely used in infants, according to a lawyer representing families of two babies that died after receiving the wrong dosage of the drug.
The Weinberg Group announced it has acquired BCG Europe, a consulting firm that specializes in product development and commercialization for the life sciences industry, particularly human pharmaceuticals.
Device manufacturing companies suffer a lack of adequate business intelligence compared with pharmaceutical companies, which are often larger and better-funded, according to a new study by Cutting Edge Information.
Congress is debating whether to amend a consumer-protection law to keep contact lens makers from shutting internet-only sellers out of the distribution loop.
Pharmaceutical industry growth has made a geographic shift in the last few years from the U.S. to other countries and will continue to materialize abroad, one analyst said at an industry conference last week.
Versions of biologic products should not be lumped together as a homogenous group, but rather placed into separate categories depending on qualities such as structure and efficacy, one drugmaker said at a recent industry conference.